ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation

Bone ◽  
2007 ◽  
Vol 40 (2) ◽  
pp. 281-292 ◽  
Author(s):  
N. Okuda ◽  
S. Takeda ◽  
K. Shinomiya ◽  
T. Muneta ◽  
S. Itoh ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Vitamin D ◽  
Bone Resorption ◽  
Bone Formation ◽  
Vitamin D Analog ◽  
Bone Marrow Ablation ◽  
Marrow Ablation

Dietary calcium supplementation stimulates bone formation and inhibits bone resorption after bone marrow ablation in mice

Bone ◽  
2010 ◽  
Vol 47 ◽  
pp. S399-S400 ◽  
Author(s):  
Jun Yan ◽  
Weiwei Sun ◽  
Chunmin Shi ◽  
Dengshun Miao
Keyword(s):  
Bone Marrow ◽  
Bone Resorption ◽  
Bone Formation ◽  
Calcium Supplementation ◽  
Dietary Calcium ◽  
Bone Marrow Ablation ◽  
Marrow Ablation

scholarly journals Inducible Activation of FGFR2 in Adult Mice Promotes Bone Formation After Bone Marrow Ablation

2017 ◽  
Vol 32 (11) ◽  
pp. 2194-2206 ◽  
Author(s):  
Wei Xu ◽  
Fengtao Luo ◽  
Quan Wang ◽  
Qiaoyan Tan ◽  
Junlan Huang ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Formation ◽  
Adult Mice ◽  
Bone Marrow Ablation ◽  
Marrow Ablation ◽  
Inducible Activation

High dose glucocorticoid hampers bone formation and resorption after bone marrow ablation in rat

2006 ◽  
Vol 69 (10) ◽  
pp. 839-846 ◽  
Author(s):  
Naoki Kondo ◽  
Kunihiko Tokunaga ◽  
Tomoyuki Ito ◽  
Katsumitsu Arai ◽  
Norio Amizuka ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Formation ◽  
High Dose ◽  
Bone Marrow Ablation ◽  
Marrow Ablation

scholarly journals Constitutively active PTH/PTHrP receptor specifically expressed in osteoblasts enhances bone formation induced by bone marrow ablation

2011 ◽  
Vol 227 (2) ◽  
pp. 408-415 ◽  
Author(s):  
Noriaki Ono ◽  
Kazuhisa Nakashima ◽  
Ernestina Schipani ◽  
Tadayoshi Hayata ◽  
Yoichi Ezura ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Formation ◽  
Bone Marrow Ablation ◽  
Pthrp Receptor ◽  
Marrow Ablation ◽  
Constitutively Active

scholarly journals Intramedullary injury combined with osteoporosis therapeutics regulates targeted local osteogenesis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yoko Miyazaki-Asato ◽  
Kiyono Koi ◽  
Hiroki Fujimoto ◽  
Kae Kakura ◽  
Hirofumi Kido ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Bone Marrow ◽  
Bone Formation ◽  
Medullary Cavity ◽  
Micro Ct ◽  
Implant Placement ◽  
Local Bone ◽  
Bone Response ◽  
Bone Marrow Ablation ◽  
Marrow Ablation

AbstractBone marrow ablation prompts transient bone formation in nearly the entire medullary cavity before marrow regeneration occurs. Here, we establish a procedure to direct bone formation in a desired particular site within the medullary cavity for support of biomedical devices. Local intramedullary injury was performed in the tibiae of rats and parathyroid hormone (PTH), alendronate, or saline was administered. Newly generated bone in the medulla was assessed by micro-CT and histology. To evaluate the function of newly generated bone, animals received intramedullary injury in tibiae followed by daily PTH. At day-14, implants were placed in the endocortical bone and the bone response to the implants was assessed. The fate of newly generated bone was compared with and without implants. We found that neither intramedullary injury nor medication alone resulted in bone formation. However, when combined, substantial bone was generated locally inside the diaphyseal medulla. Newly formed bone disappeared without implant placement but was retained with implants. Bone was especially retained around and between the implants. This study found that local bone marrow disruption followed by PTH or alendronate generated substantial cancellous bone locally in the diaphyseal medulla. This approach offers promise as a tissue engineering tool in medicine and dentistry.

scholarly journals Retardation in Bone Resorption after Bone Marrow Ablation in Klotho Mutant Mice1

Endocrinology ◽  
2000 ◽  
Vol 141 (1) ◽  
pp. 438-445 ◽  
Author(s):  
Teruhito Yamashita ◽  
Hiroyuki Yoshitake ◽  
Kunikazu Tsuji ◽  
Nanako Kawaguchi ◽  
Yo-ichi Nabeshima ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Resorption ◽  
Bone Marrow Ablation ◽  
Marrow Ablation

153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies

2002 ◽  
Vol 23 (11) ◽  
pp. 1099-1106 ◽  
Author(s):  
D. J. MACFARLANE ◽  
S. DURRANT ◽  
M. L. BARTLETT ◽  
R. ALLISON ◽  
A. J. MORTON
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Haematological Malignancies ◽  
Bone Marrow Ablation ◽  
Marrow Ablation

scholarly journals The Paradoxical Role of Uric Acid in Osteoporosis

Nutrients ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 2111 ◽  
Author(s):  
Kun-Mo Lin ◽  
Chien-Lin Lu ◽  
Kuo-Chin Hung ◽  
Pei-Chen Wu ◽  
Chi-Feng Pan ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Vitamin D ◽  
Uric Acid ◽  
Bone Resorption ◽  
Bone Formation ◽  
Inflammatory Cytokines ◽  
Bone Fracture ◽  
Health Concern ◽  
Free Oxygen Radicals ◽  
Increase Bone Resorption

Because of its high prevalence worldwide, osteoporosis is considered a serious public health concern. Many known risk factors for developing osteoporosis have been identified and are crucial if planning health care needs. Recently, an association between uric acid (UA) and bone fractures had been explored. Extracellular UA exhibits antioxidant properties by effectively scavenging free radicals in human plasma, but this benefit might be disturbed by the hydrophobic lipid layer of the cell membrane. In contrast, intracellular free oxygen radicals are produced during UA degradation, and superoxide is further enhanced by interacting with NADPH oxidase. This intracellular oxidative stress, together with inflammatory cytokines induced by UA, stimulates osteoclast bone resorption and inhibits osteoblast bone formation. UA also inhibits vitamin D production and thereby results in hyper-parathyroidism, which causes less UA excretion in the intestines and renal proximal tubules by inhibiting the urate transporter ATP-binding cassette subfamily G member 2 (ABCG2). At normal or high levels, UA is associated with a reduction in bone mineral density and protects against bone fracture. However, in hyperuricemia or gout arthritis, UA increases bone fracture risk because oxidative stress and inflammatory cytokines can increase bone resorption and decrease bone formation. Vitamin D deficiency, and consequent secondary hyperparathyroidism, can further increase bone resorption and aggravated bone loss in UA-induced osteoporosis.

Human serum and plasma have different sources of epidermal growth factor

1990 ◽  
Vol 259 (3) ◽  
pp. R545-R548 ◽  
Author(s):  
A. Lev-Ran ◽  
D. L. Hwang ◽  
D. S. Snyder
Keyword(s):  
Bone Marrow ◽  
Platelet Count ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Molecular Mass ◽  
High Performance ◽  
Regression Line ◽  
Bone Marrow Ablation ◽  
Epidermal Growth ◽  
Marrow Ablation

Epidermal growth factor (EGF) was determined by radioimmunoassay in serum, plasma, and urine of 23 patients undergoing ablative therapy followed by bone marrow transplantation. The difference between the serum and plasma values reflected the amount of EGF released from the platelets at the time of blood coagulation. Platelet-derived EGF strongly correlated with platelet count (r + 0.850, P less than 0.0001), and the intercept of the regression line was very close to zero; one platelet contained approximately 2.5 x 10(-18) g EGF. Correspondingly, when the platelet count dropped after bone marrow ablation from 222 +/- 97 to 33 +/- 13 x 10(9)/l, the serum EGF decreased from 603 +/- 222 to 65 +/- 41 pg/ml (P less than 0.0001). Plasma EGF content did not correlate with the platelet count and did not change significantly after bone marrow ablation (before and after the ablation, correspondingly, 290 +/- 80 and 332 +/- 99 pg/ml, P = 0.194). High-performance liquid chromatographic fractionation of serum and plasma showed different molecular mass distribution of EGF-immunoreactive fractions. The main molecular mass components of the plasma EGF did not change after bone marrow ablation. Urine excretion remained unchanged (320 +/- 133 and 314 +/- 173 pmol EGF/mmol creatinine). We conclude that whereas platelets are the source of serum EGF, the origin of plasma EGF is different and the search of its origin is warranted.

Sign in / Sign up

Export Citation Format

Share Document